Alexion Pharmaceuticals Inc. in New Haven announced Monday that Japan’s health ministry approved Kanuma for the treatment of patients in Japan with lysosomal acid lipase deficiency (LAL-D).
Kanuma, an enzyme replacement therapy, is the first therapy approved in Japan for the treatment of patients with LAL-D, a genetic and progressive ultra-rare metabolic disease in which patients suffer organ damage and premature death, according to Alexion.
Alexion expects patients with LAL-D in Japan will start commercial treatment with Kanuma in the third quarter this year.
Kanuma is also approved for the treatment of patients with LAL-D in the United States and European Union.
